Physician profile
Stephen Spates
NPI 1740251495
$2,477.98
in general payments reported to CMS, 2019-2025
28 companies · $708 in 2025
The $708 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $280 · 2021: $259 · 2022: $295 · 2023: $314 · 2024: $422 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $677.09 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $324.66 | 2019-2025 | |
| Convatec INC. | $183.30 | 2023-2025 | |
| Amgen INC. | $156.58 | 2020-2024 | Otezla |
| Abbvie INC. | $140.60 | 2024-2025 | |
| Incyte Corporation | $139.99 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $105.69 | 2021-2024 | Ebglyss, Taltz, Olumiant |
| Mayne Pharma Commercial LLC | $88.81 | 2023-2025 | |
| Ucb, INC. | $81.59 | 2020-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $78.10 | 2019-2023 | Siliq |
| Genzyme Corporation | $70.53 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $52.50 | 2024-2025 | Libtayo |
| Galderma Laboratories, L.P. | $46.41 | 2020-2024 | |
| Almirall LLC | $44.93 | 2021-2023 | Seysara |
| Novartis Pharmaceuticals Corporation | $34.99 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $30.02 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $27.19 | 2020 | |
| Epi Health, LLC | $26.73 | 2020 | |
| Biofrontera INC. | $25.89 | 2021 | |
| Organogenesis INC. | $21.52 | 2021 | |
| Botanix Sb INC | $18.24 | 2025 | Sofdra |
| Mission Pharmacal Company | $16.41 | 2019 | |
| Leo Pharma INC. | $16.27 | 2023 | Adbry |
| Celgene Corporation | $14.94 | 2019 | |
| Dermira, INC. | $14.93 | 2021 | |
| Nabriva Therapeutics, Plc | $13.75 | 2022 | |
| Merck Sharp & Dohme LLC | $13.54 | 2019 | |
| Journey Medical Corporation | $12.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Spates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.